Medidata Solutions, Inc. (NASDAQ:MDSO) has been given a consensus recommendation of “Buy” by the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $81.36.
Several equities research analysts have commented on MDSO shares. Zacks Investment Research lowered Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Friday, July 21st. Citigroup Inc. reiterated a “buy” rating and set a $95.00 price objective (up from $94.00) on shares of Medidata Solutions in a research note on Monday, July 24th. SunTrust Banks, Inc. boosted their price objective on Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Morgan Stanley boosted their price objective on Medidata Solutions from $74.00 to $86.00 and gave the stock an “overweight” rating in a research note on Thursday, July 20th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $78.00 price objective on shares of Medidata Solutions in a research note on Tuesday, August 22nd.
In other news, COO Michael L. Capone sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.80% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of MDSO. Acrospire Investment Management LLC purchased a new stake in shares of Medidata Solutions in the first quarter valued at approximately $121,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Medidata Solutions by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after purchasing an additional 208 shares in the last quarter. LS Investment Advisors LLC grew its position in shares of Medidata Solutions by 44.6% in the first quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock valued at $191,000 after purchasing an additional 1,021 shares in the last quarter. World Asset Management Inc purchased a new stake in shares of Medidata Solutions in the first quarter valued at approximately $201,000. Finally, Miles Capital Inc. purchased a new stake in shares of Medidata Solutions in the first quarter valued at approximately $202,000. Institutional investors and hedge funds own 97.53% of the company’s stock.
Medidata Solutions (NASDAQ MDSO) traded down 0.73% during trading on Friday, reaching $74.79. The company’s stock had a trading volume of 304,012 shares. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92. The stock has a 50-day moving average of $74.88 and a 200 day moving average of $69.50. The firm has a market capitalization of $4.23 billion, a P/E ratio of 120.82 and a beta of 1.81.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The company had revenue of $137.41 million during the quarter, compared to analyst estimates of $134.28 million. During the same period in the previous year, the business earned $0.24 EPS. Medidata Solutions’s quarterly revenue was up 19.9% on a year-over-year basis. On average, equities research analysts predict that Medidata Solutions will post $1.28 EPS for the current fiscal year.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.